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SUMMARY
Early treatment of prolonged seizures with ben-
zodiazepines given intravenously by paramedics in
the prehospital setting has been shown to be asso-
ciated with improved outcomes. However, an
increasing number of Emergency Medical System
(EMS) protocols use an intramuscular (IM) route
because it is faster and consistently achievable.
RAMPART (Rapid Anticonvulsant Medication
Prior to Arrival Trial) is a double-blind random-
ized clinical trial to determine if the efficacy of IM
midazolam is noninferior by a margin of 10% to
that of intravenous (IV) lorazepam in patients
treated by paramedics for status epilepticus (SE).
Children and adults with >5 min of convulsions
who are still seizing after paramedic arrival are
administered study medication by IM autoinjector
or IV infusion. The primary efficacy outcome is
absence of seizures at emergency department
(ED) arrival, without EMS rescue therapy. Safety
outcomes include acute endotracheal intubation
and recurrent seizures. Secondary outcomes
include timing of treatment and initial seizure ces-
sation. At the time of writing this communication,
enrollment of all subjects is near completion and
the study data will soon be analyzed.
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Background
Early treatment of SE by paramedics reduces the num-
ber of patients with persistent seizures on ED arrival and
the number admitted to the intensive care unit (ICU) for
refractory status (Alldredge et al., 2001). However, the
optimal agent for prehospital treatment of SE is unknown.
Intramuscular midazolam is an increasingly popular
choice because of its ease of administration and practical-
ity for EMS use, but the safety and efficacy of midazolam
or the IM route of administration have not been studied in
a randomized controlled trial (Warden & Frederick,
2006). We hypothesized that in the prehospital treatment
of SE, the efficacy of IM midazolam is not inferior to that
of intravenous IV lorazepam, as determined by the
proportion of subjects with termination of clinically evi-
dent seizure at arrival in the ED after a single dose of study
medication and without use of rescue medication.
Methods
This is a double-blind randomized noninferiority
clinical trial of the efficacy of IM midazolam versus IV
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lorazepam in the prehospital treatment of SE by paramed-
ics. The trial is being carried out by the Neurological
Emergencies Treatment Trials (NETT) network, a multi-
disciplinary clinical trials infrastructure funded by the
National Institute of Neurological Disorders and Stroke
(NINDS). The NETT is composed of 17 enrollment Hub
sites, a Clinical Coordinating Center, and a Statistical
Data Management Center. The Hubs are academic medi-
cal centers that coordinate enrollment within a number of
Spokes consisting of EMS agencies and other regional
academic and community hospitals. RAMPART has
relied on more than 4,000 paramedics, 33 EMS agencies,
and 79 receiving hospitals across the United States.
Approximately 1,000 adult and pediatric patients with
continuing seizure activity after EMS arrival and meeting
all inclusion and exclusion criteria are being enrolled and
randomized in this trial. All subjects receive active treat-
ment by either IM or IV routes of administration. Adults
and children ‡40 kg who are randomized to active IM
therapy are treated with 10 mg midazolam IM followed
by IV placebo. Adults and children ‡40 kg who are
randomized to IV active therapy are treated with IM pla-
cebo followed by 4 mg lorazepam IV. The weight of chil-
dren is estimated from their length using a length-based
weight-estimation tape that is included in each study box.
Active therapy in children estimated to be <40 kg is either
5 mg midazolam IM or 2 mg lorazepam IV. Children esti-
mated to be <13 kg are not enrolled.
The specially designed study box incorporates a voice
recorder activated by opening the box. Study personnel
are instructed to provide verbal statements at the following
times: IM treatment, IV access obtained, IV administered,
administration of any rescue treatments, when and if
convulsions are observed to stop, and whether the subject
is seizing on arrival at the ED. The study box has an inter-
nal clock that time-stamps all statements.
In situations where starting an IV is difficult, medics
are expected to continue attempts for at least 10 min.
An intraosseous (IO) route can be used at any time in lieu
of IV access. Rescue therapy, as dictated by local EMS
protocol, is expected to be used in subjects who are still
seizing 10 min after the last study medication is adminis-
tered. In cases for which there is a delay in starting the IV
and a subject no longer has seizures before IV study drug
is given, the study intervention will be considered and IV
study medication does not need to be used. When seizures
are observed to resume later during EMS transport, medics
are instructed to use rescue therapy defined by local EMS
protocol.
The study is being conducted under 21 CFR 50.24, U.S.
Food and Drug Administration (FDA) regulations govern-
ing emergency clinical research performed with exception
from informed consent (EFIC) (FDA, 2005). An EFIC
plan for the trial was included in the investigational new
drug (IND) application submitted to the FDA and was
approved by the institutional review board (IRB) at the
Clinical Coordinating Center. IRBs at each NETT site
have reviewed community consultation and public disclo-
sure activities and provided local approval. Every EMS
system participating in the study is covered under a new or
existing Federal Wide Assurance delineating an IRB of
record for that system. Subjects or their legally authorized
representatives are notified about enrollment in the trial
by the study team as soon as possible, and they are asked
for approval for the study team to continue collecting data
until the subject’s end of study.
Outcomes
The primary outcome measure is the binary outcome
variable measuring whether or not there is termination of
convulsive seizure activity prior to arrival in the ED after
an initial dose of study medication without the need for a
second ‘‘rescue’’ dose of benzodiazepine by EMS. Deter-
mination of termination of convulsive seizure activity
upon arrival at the receiving emergency department is
made clinically by the attending emergency physician
treating the subject. Key secondary outcome measures
include times from EMS arrival to termination of seizure
and from initiation of treatment to termination of seizure.
Other secondary outcomes include frequency of endotra-
cheal intubation, the frequency and duration of hospital-
ization and of ICU admission, and the frequency of acute
seizure recurrence. Time data are collected using an
instrumented logger device that determines time of arrival
and records voice time-stamps when medications are
given or convulsions are noted to have stopped.
Analysis
The primary analysis used in this trial will test the
hypothesis that IM midazolam is not less effective than IV
lorazepam on the primary end point by more than an abso-
lute difference of 10% (i.e., noninferiority margin) (Dun-
nett & Gent, 1977). Based on preliminary studies we
estimate that 70% of subjects will terminate seizure prior
to ED arrival after the initial dose of IV lorazepam. An
absolute difference in the proportion of terminated sei-
zures at ED arrival of <10% between the two treatment
groups is considered to be clinically unimportant and is
defined as the noninferiority margin. The value of this
margin is based on a combination of statistical and clinical
judgments and was chosen to ensure that the overall suc-
cess (termination of seizure) of the new treatment (IM
midazolam) has a clinically relevant superiority over a
putative placebo as well as a clinically unimportant differ-
ence from the currently used benzodiazepines. Based on
the above information and taking into consideration the
planned interim analysis, the study is powered to assure
>90% likelihood of identifying less than a 10% absolute
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difference in success rates between the two treatment
groups. Sample size estimation is based on the comparison
of independent proportions with a 1:1 randomization
scheme and a one-sided type I error rate of 0.025. The
maximum sample size required for randomization is 890
subjects (445 per treatment group). Due to the potential
recurrence rate in patients with SE, the total sample size is
inflated by 15% to account for multiple enrollments of a
study subject. Subjects will be independent for the
primary analysis. Therefore approximately 1,024 subjects
will be randomized.
Progress
As of the submission of this manuscript, subject enroll-
ment was completed with a total enrollment of 1,023
(Fig. 1). Analysis of data is currently underway.
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Figure 1.
Projected versus actual subject accrual for RAMPART.
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